Presented at TIDES Europe 2022 by Gerard Platenburg - ProQR Therapeutics
Published on at TIDES EuropeLink Download
A new RNA editing technology, called Axiomer®, proposes to use the cells own editing machinery and specific Editing Oligonucleotides (EONs) enabling single nucleotide edits to RNA to reverse a mutation or change a protein. This technology could have the potential to become a new class of medicine and to prevent or treat currently untreatable diseases.
Gerard is a co-founder and has served as our Chief Scientific Officer since 2022, following his tenure as Chief Innovation Officer from 2014 to 2022. Gerard has an extensive background in RNA modulation and orphan drug discovery and development and is currently in charge of our Innovation unit.